Wild Turtle Week offers education, ideas to protect Iowa's native species
Iowa is home to 13 wild turtle species, nearly all of which are in need of conservation action, or are endangered due to a loss of habitat and road-related mortalities, according to the Iowa Department of Natural Resources.
Iowans can learn about these turtles and how to help conserve the aquatic and semi-aquatic reptiles during Wild Turtle Week, June 9-13.
The eastern spiny softshell turtle, which is found throughout Iowa and the central portion of the country, lives mostly in the water and utilizes a method of absorbing oxygen through their skin and throat that is sometimes called 'butt breathing' according to Partners in Amphibian and Reptile Conservation, or PARC.
Per their name, the turtles do not have a hard shell and rely on their speed for protection. PARC suggests leaving these long-necked and snouted turtles alone if spotted out of the water, as they might be laying eggs.
Snapping turtles are also easily recognizable by their long spiny tails, shells and big, sharp beaks. Certain species of snapping turtle are listed as threatened by the U.S. Fish and Wildlife service which identified habitat loss, commercial and recreational fishing and nest predation as factors contributing to the population decline.
Wood turtles and yellow mud turtles are both listed as endangered in Iowa due to habitat loss and water pollution. Ornate box turtles, and eastern musk turtles are listed as threatened, along with the Blanding's turtle.
DNR partnered with Blank Park Zoo and Iowa State University to raise and release nearly 60 Blanding's turtles back into the Iowa landscape. The group released the turtles into the wild June 4.
According to U.S. FWS, these turtles can live for up to 70 years and often travel great distances, which exposes them to dangerous road crossings.
The western painted turtle, found across the state, is known for its bright red, yellow and black colored undersides. This small turtle, along with the red-eared slider, are two turtles that DNR said are not in need of conservation action.
Iowans can help turtles by avoiding them in roadways, and when possible, stopping to help move them across the roads. DNR said to always move turtles the same direction they were headed when helping them across a street.
It's also important to never pick up a turtle by its tail, as this can damage the reptile's spine. A press release from DNR said wetland, grassland and forest preservation can also help to save turtle habitat in Iowa.
Iowans with a keen eye for turtle identification can submit their observations online to Reptiles and Amphibians of Iowa, which charts species populations across the state. The website also has valuable photos and information to help identify turtle varieties.
PARC encourages folks across country to celebrate wild turtle week by sharing their turtle photos on social media with #ShellebrateTurtles. The organization also has webinars and other online resources with lots of turtle facts.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Boston Globe
2 days ago
- Boston Globe
Rabbits with ‘horns' in Colorado are being called ‘Frankenstein bunnies.' Here's why.
The virus likely influenced the centuries-old jackalope myth in North America, which told of a rabbit with antlers or horns, among other animal variations. The disease in rabbits also contributed to scientists' knowledge about the connection between viruses and cancer, such as the human papillomavirus that causes cervical cancer. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up This photo provided by the Iowa Department of Natural Resources shows a deceased Eastern cottontail rabbit infected with Shope papillomavirus in October 2021. Uncredited/Associated Press Advertisement The virus in rabbits was named after Dr. Richard E Shope, a professor at The Rockefeller University who discovered the disease in cottontails in the 1930s. News about the rabbit sightings in Fort Collins, 65 miles north of Denver, started getting attention after residents started spotting them around town and posting pictures. Kara Van Hoose, a spokesperson for Colorado Parks and Wildlife, told The Associated Press on Wednesday that the agency has been getting calls about the rabbits seen in Fort Collins. But she said that it's not uncommon to see infected rabbits, especially in the summer, when the fleas and ticks that spread the virus are most active. The virus can spread from rabbit to rabbit but not to other species, including humans and pets, she said. Advertisement The growths resemble warts but can look like horns if they grow longer, Van Hoose said. The growths don't harm rabbits unless they grow on their eyes or mouths and interfere with eating. Rabbits' immune systems are able to fight the virus and, once they do, the growths will disappear, she said. ___ Finley reported from Norfolk, Virginia.
Yahoo
3 days ago
- Yahoo
AST SpaceMobile Just Revealed New Satellite Launch Plans. How Should You Play ASTS Stock Here?
Space-based operations company AST SpaceMobile (ASTS) recently announced its plan to deploy 45 to 60 satellites into orbit by 2026. With six satellites in orbit — five of which are fully operational and one a test satellite— the company's target is quite hefty. AST SpaceMobile plans to make orbital launches 'every one to two months on average' during this year and the next. The company is also on target to complete 40 satellites equivalent of microns by early 2026 to support multiple space-based cellular broadband services. The company is also set to gain new spectrum priority rights, as it has announced the acquisition of global S-Band spectrum priority rights held under the auspices of the International Telecommunication Union (ITU). More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! With such operational strides, how should you play this space giant? About AST SpaceMobile Stock Founded in 2017 and headquartered in Midland, Texas, AST SpaceMobile is a satellite communications company that develops a space-based cellular broadband network designed to connect directly to standard mobile phones without the need for ground-based infrastructure. The company operates low Earth orbit (LEO) satellites, which enable seamless mobile coverage in remote and underserved areas of the world. AST SpaceMobile also has a growing rivalry with SpaceX. The companies compete to deliver space-based internet, with AST targeting phones directly and SpaceX focusing on satellite broadband via Starlink. By partnering with leading mobile network operators worldwide, AST SpaceMobile's operations blend advanced space technology with telecommunications to provide low-latency, high-speed mobile service directly from space. The company currently has a market capitalization of $15.8 billion. ASTS stock has enjoyed significant investor attention over the past year. Over the past 52 weeks, shares have gained 131%. Just for comparison, the broader S&P 500 Index ($SPX) has gained only 18% over the same period. Strong market sentiments led ASTS stock to a 52-week high of $60.95 in July. So far this year, the stock is up by 128%. After plans of the satellite launches were revealed, shares increased 8% intraday. AST SpaceMobile's Topline Is Growing On Aug. 11, AST SpaceMobile reported its second-quarter results for fiscal 2025. The company's quarterly revenues increased by 28% from the prior-year period to $1.16 million. While AST continues to post deep losses, investors have taken note of its operational strides. AST SpaceMobile's attributable net loss climbed 37% year-over-year (YOY) from $72.55 million to $99.39 million. However, its loss per share declined from $0.51 to $0.41 over the same period. Last month, the company closed a private offering of $575 million aggregate principal amount of convertible senior notes due 2032. The financing would be used to scale and develop its operations. As of June 30, 2025, AST SpaceMobile had cash, cash equivalents, and restricted cash of $939.4 million, with over $1.5 billion in balance sheet cash, cash equivalents, and restricted cash, pro forma for convertible notes offering and sales under the now-terminated at-the-market (ATM) facility. Wall Street analysts expect AST SpaceMobile to reduce its losses in the future. For the third quarter, the company's loss per share is expected to narrow by 29% from the year-ago value to $0.17. Next year, loss per share is forecast to improve by 28% to $0.73. What Do Analysts Think About AST SpaceMobile Stock? Wall Street analysts remain cautiously optimistic about AST SpaceMobile. Recently, analysts at Scotiabank lowered the price target from $45.40 to $42.90. However, the firm did not change its investment thesis and still maintains a 'Sector Perform' rating on ASTS stock. Analysts at BofA Securities initiated coverage on AST SpaceMobile stock with a 'Neutral' rating and a $55 price target. BofA Securities analysts based their prediction on 'early stage, high projected growth," and the 'outyear free cash flow generation nature of the business.' B. Riley Securities is bullish on the company's prospects. Analyst Mike Crawford raised the price target on the stock from $44 to $60, while maintaining a 'Buy' rating, following the company's announcement of its private offering. Wall Street analysts are soundly optimistic about AST SpaceMobile, giving it a consensus 'Moderate Buy' rating overall. Of the nine analysts rating the stock, a majority of six analysts rate it a 'Strong Buy,' while three analysts take a middle-of-the-road approach with a 'Hold' rating. The consensus price target of $47.36 is below current levels. However, the Street-high price target of $60 indicates potential upside of 27%. Key Takeaways There are reasons to be excited about AST SpaceMobile's prospects, as the company remains on track to grow significantly in an emerging space. While the satellite plans are ambitious, they are also fully funded. The company's cash balance also remains at a solid level. Therefore, ASTS stock might be a solid buy now. On the date of publication, Anushka Dutta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
